Venture capital investment in biopharmaceutical companies has been remarkable throughout 2020, both in terms of individual company fundraisings and new VC funds, including two funds totaling $755m that were announced on 23 September.
Longitude Capital closed its fourth and largest fund to date – Longitude Venture Partners IV LP (LVP4) – with $585m...






